Advantages:
- Directly delivers remdesivir in ophthalmic drops to the eye cells potentially minimizing systemic side effects.
- Formulation is designed to prevent disease transmission via the eyes and to treat conjunctivitis caused by infection.
- Nanoparticulate formulation meets pharmaceutical delivery standards.
Summary:
COVID-19, caused by SARS-CoV-2, can affect the eyes, causing viral conjunctivitis, and can spread through contaminated hands touching the face. Preventing ocular transmission is crucial as the virus can enter through the eye’s mucous membranes. Developing antiviral therapies and multimodal approaches is essential to prevent and treat eye infections caused by the virus.
To prevent eye infections caused by the virus, researchers formulated an ophthalmological composition comprising a nanoparticle comprising remdesivir, or a pharmaceutically acceptable salt thereof, in a concentration of about 15 wt. %, in ophthalmic drops. The formulation demonstrated in vitro activity against SARS-CoV-2. These drops can be administered several times a day and were tested on human corneal epithelial and conjunctival cell lines. HPLC and MTT assay ensure indicate the eye drops' effectiveness and safety and meet pharmaceutical development standards. To assess cell viability and cytotoxicity. Additionally, the drops aim to reduce inflammation and cytokine release in eye cells exposed to the virus’s spike protein to eliminate the virus from ocular surfaces and reduce transmission.
The above images illustrate the mechanism of ocular drug delivery for remdesivir and ARBs, focusing on inhibiting the interaction of the coronavirus spike protein with ACE2.
Desired Partnerships:
- License
- Sponsored Research
- Co-Development